The Evidence for Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Neutrophil Disorders: A Comprehensive Review by the Inborn Errors Working Party Group of the EBMT

Shahrzad Bakhtiar; Bella Shadur; Polina Stepensky

doi:10.3389/fped.2019.00436

The Evidence for Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Neutrophil Disorders: A Comprehensive Review by the Inborn Errors Working Party Group of the EBMT

Front Pediatr. 2019 Oct 24:7:436. doi: 10.3389/fped.2019.00436. eCollection 2019.

Authors

Shahrzad Bakhtiar¹, Bella Shadur^{2

3

4}, Polina Stepensky²

Affiliations

¹ Division for Pediatric Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Frankfurt, Germany.
² Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem, Israel.
³ Department of Immunology, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
⁴ Graduate Research School, University of New South Wales, Kensington, NSW, Australia.

Abstract

Congenital disorders of the immune system affecting maturation and/or function of phagocytic leucocytes can result in severe infectious and inflammatory complications with high mortality and morbidity. Further complications include progression to MDS/AML in some cases. Allogeneic stem cell transplantation is the only curative treatment for most patients with these diseases. In this review, we provide a detailed update on indications and outcomes of alloHSCT for congenital neutrophil disorders, based on data from the available literature.

Keywords: granulocyte colony-stimulating factor; hematopoietic stem cell transplantation; leukemia; neutropenia; neutrophils.

Publication types

Review